ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
128.957,09
2,64%
S&P 500
5.638,94
2,13%
US Dollar vs BRL
5,7456
0,02%
Bitcoin
84.273,91
0,37%
Brent Oil
70,285
0,00%
As Melhores Corretoras Online
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Geron Corp (GERN)

  7. Geron Corp (GERN) Notícias

GERN

Geron (GERN)

Geron Corp
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:GERN
DataHoraFonteTítuloCódigoCompanhia
11/03/202517:54Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GERNGeron Corp
03/03/202508:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GERNGeron Corp
26/02/202509:30Business WireGeron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsNASDAQ:GERNGeron Corp
21/02/202511:00Business WireGeron to Participate at Upcoming Investor Conferences in March 2025NASDAQ:GERNGeron Corp
19/02/202518:15Business WireGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:GERNGeron Corp
03/02/202511:00Business WireGeron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025NASDAQ:GERNGeron Corp
10/01/202518:05Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:GERNGeron Corp
13/12/202408:36Business WireGeron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDSNASDAQ:GERNGeron Corp
10/12/202411:00Business WireGeron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior TherapiesNASDAQ:GERNGeron Corp
10/12/202411:00Business WireGeron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with MyelofibrosisNASDAQ:GERNGeron Corp
27/11/202411:00Business WireGeron to Participate in the 7th Annual Evercore ISI HealthCONx ConferenceNASDAQ:GERNGeron Corp
14/11/202411:31Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:GERNGeron Corp
14/11/202408:25Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:GERNGeron Corp
11/11/202418:30Business WireGeron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and DevelopmentNASDAQ:GERNGeron Corp
11/11/202411:00Business WireGeron to Participate in the Stifel 2024 Healthcare ConferenceNASDAQ:GERNGeron Corp
07/11/202409:10GlobeNewswire Inc.Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 MillionNASDAQ:GERNGeron Corp
07/11/202409:01Business WireGeron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon AdvisorsNASDAQ:GERNGeron Corp
07/11/202409:00Business WireGeron Corporation Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:GERNGeron Corp
05/11/202411:00Business WireGeron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (imetelstat) in Myeloid Hematologic MalignanciesNASDAQ:GERNGeron Corp
15/10/202417:30Business WireGeron to Announce Third Quarter 2024 Financial Results on November 7, 2024NASDAQ:GERNGeron Corp
09/09/202417:35Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:GERNGeron Corp
09/09/202417:15Business WireGeron Corporation Announces Appointment of Jim Ziegler as Chief Commercial OfficerNASDAQ:GERNGeron Corp
08/08/202408:00Business WireGeron Corporation Reports Second Quarter 2024 Financial Results and Business HighlightsNASDAQ:GERNGeron Corp
26/07/202408:30Business WireGeron Announces Updated NCCN Guidelines® Recommending RYTELO™ (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDSNASDAQ:GERNGeron Corp
23/07/202417:15Business WireGeron Corporation Announces Chief Commercial Officer to Depart at End of August 2024NASDAQ:GERNGeron Corp
18/07/202417:30Business WireGeron to Announce Second Quarter 2024 Financial Results on August 8, 2024NASDAQ:GERNGeron Corp
08/07/202416:44Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GERNGeron Corp
06/06/202422:58Business WireGeron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent AnemiaNASDAQ:GERNGeron Corp
02/05/202408:00Business WireGeron Corporation Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:GERNGeron Corp
25/04/202417:30Business WireGeron to Announce First Quarter 2024 Financial Results on May 2, 2024NASDAQ:GERNGeron Corp
 Apresentando as notícias mais relevantes sobre:NASDAQ:GERN

Seu Histórico Recente

TG
N9B
Bandai Namco
XE
NFC
Netflix
TG
I5M
Iron Mountain
TG
ISHA
Intershop Communications
TG
PODB
Poland
XE
SLYG
Shelly
TG
0EEB
Republic of Romania
TG
FESE
Fidelity ESG USD EM Bond...
TG
CBRS
First Trust Global Funds
TG
ISAA
Israel Saat
ASX
EPX
EP&T Global
XE
FYEI
Fidelity EUR HY Corp Bon...
TG
FHTG
MFS Meridian Funds
TG
SJ3
Sherwin Williams
TG
AMEI
Amundi Luxembourg
TG
34LA
Alpine Immune Sciences
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios